• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by LENSAR Inc.

    2/28/25 5:10:05 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email
    S-8 1 lnsr-s8-2025.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on February 28, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

    LENSAR, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

     

    32-0125724

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    2800 Discovery Drive,

    Orlando, Florida

    32826

    (Address of Principal Executive Offices)

    (Zip Code)

     

    2020 Incentive Award Plan

    2020 Employee Stock Purchase Plan

    (Full title of the plans)

    Nicholas T. Curtis

    Chief Executive Officer

    LENSAR, Inc.

    2800 Discovery Drive,

    Orlando, FL 32826

    (888) 536-7271

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    B. Shayne Kennedy

    Drew Capurro

    Latham & Watkins LLP

    650 Town Center Drive, 20th Floor

    Costa Mesa, CA 92626

    (714) 540-1235

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☒

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 699,259 shares of common stock, par value $0.01 per share (the “Common Stock”), of LENSAR, Inc. (the “Registrant”) issuable under the following employee benefit plans for which registration statements of the Registrant on Form S-8 (File Nos. 333-249323, 333-263276, 333-270703 and 333-277665) are effective: (i) the 2020 Incentive Award Plan, pursuant to the automatic annual increase provision therein, which added 582,716 shares of Common Stock, and (ii) the 2020 Employee Stock Purchase Plan, pursuant to the automatic annual increase provision therein, which added 116,543 shares of Common Stock.

     

    Pursuant to General Instruction E of Form S-8, the contents of the above-referenced prior registration statements are incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    Exhibit

     

     

     

     

     

    Incorporated by Reference

     

    Filed

    Number

     

     

    Exhibit Description

     

    Form

     

    File Number

    Filing Date

     

    Exhibit

     

    Herewith

     

     

     

     

     

     

     

     

    3.1

     

     

    Amended and Restated Certificate of Incorporation of LENSAR, Inc.

     

    8-K

     

    001-39473

    10/02/2020

     

    3.1

     

     

     

     

     

     

     

     

     

     

    3.2

     

     

    Amended and Restated Bylaws of LENSAR, Inc.

     

    10-Q

     

    001-39473

    11/07/2024

     

    3.2

     

     

     

     

     

    3.3

     

     

    Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock filed May 18, 2023

     

    8-K

     

    001-39473

    05/18/2023

     

    3.1

     

     

     

     

     

     

    4.1

     

     

    Form of Certificate of Common Stock

     

    10/A

     

    001-39473

    09/14/2020

     

    4.1

     

     

     

     

    5.1

     

     

    Opinion of Latham & Watkins LLP

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

    23.1

     

     

    Consent of Independent Registered Public Accounting Firm (PricewaterhouseCoopers LLP)

     

     

     

     

     

     

     

     

    X

     

     

    23.2

     

     

    Consent of Latham & Watkins LLP (included in Exhibit 5.1)

     

     

     

     

     

     

     

     

    X

     

     

    24.1

     

     

    Power of Attorney (included on signature page)

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

    99.1

     

     

    2020 Incentive Award Plan

     

    S-8

     

    001-39473

    10/05/2020

     

    10.1

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.2

     

     

    Form of Restricted Stock Award Agreement pursuant to 2020 Incentive Award Plan

     

    S-8

     

    001-39473

    10/05/2020

     

    10.2

     

     

     

     

     

     

     

     

     

     


     

     

    99.3

     

     

    Form of Stock Option Agreement pursuant to 2020 Incentive Award Plan

     

    10-K

     

    001-39473

    03/03/2022

     

    10.5

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.4

     

     

    Form of Restricted Stock Unit Agreement pursuant to 2020 Incentive Award Plan

     

    10-K

     

    001-39473

    03/03/2022

     

    10.6

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.5

     

     

    Form of Performance Restricted Stock Unit Agreement – Director Deferral pursuant to 2020 Incentive Award Plan

     

    10-Q

     

    001-39473

    05/09/2024

     

    10.3

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.6

     

     

    2020 Employee Stock Purchase Plan

     

    10/A

     

    001-39473

    09/14/2020

     

    10.5

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    107.1

     

     

    Filing Fee Table

     

     

     

     

     

     

     

     

    X

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Orlando, State of Florida, on February 28, 2025.

     

     

     

    LENSAR, INC.

     

     

    By

     

    /s/ Nicholas T. Curtis

     

     

    Nicholas T. Curtis

     

     

    Chief Executive Officer

    SIGNATURES AND POWER OF ATTORNEY

    We, the undersigned officers and directors of LENSAR, Inc., hereby severally constitute and appoint Nicholas T. Curtis and Thomas R. Staab, II, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign this registration statement and any and all amendments (including post-effective amendments) to this registration statement and all documents relating thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

     

     

    Name

    Title

    Date

    /s/ Nicholas T. Curtis

    Chief Executive Officer and Director

    (principal executive officer)

    February 28, 2025

    Nicholas T. Curtis

     

     

     

     

    /s/ Thomas R. Staab, II

    Chief Financial Officer

    (principal financial officer)

    February 28, 2025

    Thomas R. Staab, II

     

     

     

     

     

     

     

    /s/ Kendra W. Wong

    Principal Accounting Officer

    (principal accounting officer)

    February 28, 2025

    Kendra W. Wong

     

     

     

     

    /s/ William J. Link, Ph.D.

    Chairperson of the Board of Directors

    February 28, 2025

    William J. Link, Ph.D.

     

     

     

     

    /s/ Thomas B. Ellis

     

    Director

     

    February 28, 2025

    Thomas B. Ellis

     

     

     

     

     

     

     

     

     

    /s/ Todd B. Hammer

     

    Director

     

    February 28, 2025

    Todd B. Hammer

     

     

     

     

     

     

     

     

     

     


     

    /s/ Richard L. Lindstrom, M.D.

    Director

    February 28, 2025

    Richard L. Lindstrom, M.D.

     

     

     

     

    /s/ Elizabeth G. O’Farrell

    Director

    February 28, 2025

    Elizabeth G. O’Farrell

     

     

     

     

    /s/ Aimee S. Weisner

    Director

    February 28, 2025

    Aimee S. Weisner

     

     

     

     

    /s/ Gary M. Winer

    Director

    February 28, 2025

    Gary M. Winer

     

     

     


    Get the next $LNSR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,826 shares, decreasing direct ownership by 1% to 171,535 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:07 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:11 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,262 shares, decreasing direct ownership by 0.63% to 359,461 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:06 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    SEC Filings

    View All

    LENSAR Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - LENSAR, Inc. (0001320350) (Filer)

    12/19/25 4:01:27 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by LENSAR Inc.

    SCHEDULE 13G - LENSAR, Inc. (0001320350) (Subject)

    11/13/25 12:03:17 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by LENSAR Inc.

    10-Q - LENSAR, Inc. (0001320350) (Filer)

    11/6/25 4:01:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    9/6/24 9:00:13 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/29/24 6:05:46 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/23/24 6:52:16 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units ("RSUs"). The RSUs were granted as of September 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal installments on each anniversary of the grant date, subject to the

    9/2/25 4:01:44 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG initiated coverage on LENSAR with a new price target

    BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

    11/22/21 6:09:40 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    3/2/21 8:10:50 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    2/24/21 6:12:20 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/14/24 4:05:39 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/13/24 4:30:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Financials

    Live finance-specific insights

    View All

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports First Quarter 2025 Results and Provides Business Update

             14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

    5/8/25 7:00:42 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

    31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financia

    2/27/25 7:00:11 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care